Human immunodeficiency virus (HIV) affects more than 1 million individuals in the United States and over 40 million people worldwide. 1 Advances in combination antiretroviral treatment (cART) have transformed HIV from a rapidly fatal disease to a manageable chronic condition. [2] [3] [4] The proportion of older HIV-infected (HIVþ) individuals is rapidly growing. More than half of all HIVþ individuals in the United States are expected to be greater than 50 years old by 2015. 5 HIV infected (HIVþ) individuals receiving cART can now expect to live almost as long as HIV-uninfected (HIV-) individuals. 6 Despite these advances, eradication of HIV from the brain has not occurred. The prevalence of HIV-associated neurocognitive disorders (HAND) has remained constant ( 40%) despite more available and effective antiretrovirals. 7, 8 Soon after seroconversion, HIV rapidly spreads throughout the brain. Some HIVþ individuals who have effective plasma HIV-1 RNA suppression with cARTstill develop HAND. 9 The continued presence of HAND in the cART era may result from nonmutually-exclusive factors including irreversible injury prior to initiating cART, persistent HIV-1 RNA in the central nervous system (CNS) compartment, 10 antiretroviral toxicities, [11] [12] [13] and/or persistent low-level inflammation in the CNS. 14 A major effort has begun to optimize therapy for HAND by addressing persistent HIV reservoirs and immunologic activation in the brain. 
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Abstract
Human immunodeficiency virus (HIV) enters the brain soon after seroconversion and can cause HIV-associated neurocognitive disorders (HAND). Although the more severe and progressive forms of HAND are less prevalent due to combination antiretroviral therapy (cART), 40% of HIV-infected (HIVþ) patients continue to have cognitive impairment. Some HIVþ individuals who have effective plasma HIV-1 RNA suppression with cART still develop HAND. It is often difficult to diagnose HAND in the outpatient setting as detailed neuropsychological performance testing is required. Additional biomarkers that are relatively easy to obtain and clinically relevant are needed for assessing HIV-associated neuropathologic changes. Recently developed noninvasive magnetic resonance imaging (MRI) techniques have great potential to serve as biomarkers. The authors review the application of some of these neuroimaging techniques, magnetic resonance spectroscopy (MRS), volumetric MRI, diffusion tensor imaging (DTI), functional MRI (fMRI), in HIVþ individuals. Each of the neuroimaging methods offers unique insight into mechanisms underlying neuroHIV, could monitor disease progression, and may assist in evaluating the efficacy of particular cART regimens. It is hoped that considerable progress will continue to occur such that some of these neuroimaging methods will be incorporated across multiple sites and included in future HAND guidelines.
HAND is often difficult to characterize in the typical outpatient visit (15-30 min). Multiple connections throughout the brain are often affected leading to the complex series of clinical signs and symptoms. 15 Recent criteria have subdivided HAND into three categories: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV associated dementia (HAD). 8 These definitions are based upon an individual's performance on neuropsychological performance (NP) testing and self-reported activities of daily living. However, limitations exist with the current HAND criteria. 16 Often NP testing ( 3 h) is performed in a research setting at certain sites. 8 A continuum of HAND may occur instead of set distinctions. 17 Unlike other neurodegenerative disorders (i.e., Alzheimer's disease), 18 additional biomarkers (cerebrospinal fluid [CSF] or neuroimaging) have not been included in the HAND diagnosis. Biomarkers of HAND that are both easy to perform and clinically relevant remain an unmet need.
Neuroimaging techniques may therefore have increased utility in the diagnosis and management of HAND. A variety of novel noninvasive neuroimaging techniques have been developed and hold great promise as they often can be added to conventional sequences. Of note, three magnetic resonance imaging (MRI) techniques have been used in the neuroHIV research setting: metabolic (magnetic resonance spectroscopy [MRS]), structural (MRI volumetrics and diffusion tensor imaging (DTI)), and functional (functional MRI [fMRI]). This review is not meant to be a comprehensive review of all MRI techniques and does not focus on other neuroimaging modalities (e.g., positron emission tomography [PET] 19 ).
Cerebral Metabolite Imaging using Magnetic Resonance Spectroscopy
MRS has been one of the most consistently used neuroimaging methods during the pre-and post-cART eras. 20-23 A current PubMed search reveals more than 75 articles that describe studies that have used this technique to detect HIVassociated changes in cerebral metabolites (key search terms: "MRS," "brain," and "HIV"). Please see ►Table 1 for a select list of MRS studies performed in HIVþ patients. MRS detects the signal produced by protons of specific molecules within a volume of brain. Signal amplitude of a particular molecule X (A X ) of interest is proportional to the number of moles of X (N X ) with the brain volume (V B ) interrogated. Typical molecules measured include (1) N-acetyl aspartate (NAA)-a neuronal marker, (2) choline (Cho)-a marker of cellular proliferation and inflammatory response, (3) creatine (Cr)a measure of brain energy metabolism and reference marker, (4) myo-inositol (MI)-a marker of gliosis, and (5) glutamine (Gln)/glutamate (Glu)-measures of neurotoxicity due to excess N-methyl-D-aspartate (NMDA) receptor activation.
In general, MRS can be performed on conventional MRI scanners, but technical assistance is needed to ensure goodquality scans are obtained. MRS studies should be carefully performed to ensure homogeneity of the magnetic field and suppression of the water signal. 24 Depending on both the institution and time available for scanning, single-or multi-voxel MRS has been acquired using a variety of acquisition techniques to yield qualitative versus semiquantitative versus quantitative values. Due to quantification limitations, calibration is often performed using a phantom or an internal signal (e.g. water (H 2 O) or Cr). This can result in metabolite ratios rather than absolute concentrations (e.g., NAA/Cr).
Though often limited to certain brain regions (e.g., frontal gray, frontal or parietal white matter, and basal ganglia), MRS provides key insights into the dynamic changes in the brain metabolic profile from primary ( 1 year since seroconversion) to chronic (> 1 year since seroconversion) infection. Soon after seroconversion, MRS metabolites have been shown to be affected. 21, [25] [26] [27] HIVþ patients scanned during the first year of infection have increased Cho/Cr in the frontal and white matter 21 compared with HIV-controls. A subsequent study confirmed these findings with primary HIVþ individuals having higher Cho/ Cr in the basal ganglia compared with HIV-controls. 25 Observed MRS changes are correlated with markers of CNS infection and inflammation (detectable HIV-1 RNA and chemokines) 25 and neuronal injury (neurofilament light chain). 27 Within chronically infected patients, brain metabolite changes are also evident. Many studies have often observed reductions in NAA and concomitant increases in Cho and MI. 22, [28] [29] [30] [31] More recent MRS studies performed at higher magnetic fields using newer analysis methods have demonstrated reductions in Glu 32 and Gln. 29 Observed MRS changes in chronically infected HIVþ patients are proportional to the degree of cognitive impairment. 22, 29 While increases in MRS markers of inflammation (Cho and MI) are seen in cognitively normal HIVþ patients, greater changes in inflammation (Cho and MI) and neuronal loss (NAA/Cr and Glu/ Cr) are observed in HAND patients. 22, 29, 32 The introduction of cART has dramatically reduced the more severe forms of HAND and can also lead to improvements, but not normalization, of brain metabolites. 31, 33, 34 Early treatment with cART may be neuroprotective and mitigate the early inflammatory changes seen in primary HIVþ patients. Commencement of therapy soon after diagnosis normalizes Cho/Cr in the basal ganglia within 6 months. 26 Several clinical trials have started to include MRS markers to evaluate the efficacy of adjunctive therapy for HAND. 35 This technique may have great potential in future early prevention studies.
Increasing evidence has also suggested that certain antiretrovirals may cause mitochondrial toxicity and lead to neuronal loss. 12, 36 Chronically infected HIVþ patients on cART regimens that included nucleotide reverse transcriptase inhibitors (NRTIs) had significant reductions in NAA in the frontal white matter compared with HIV-controls. HIVþ individuals receiving alternative cART regimens that did not include NRTIs exhibited intermediate decreases in NAA. 37 A more recent study has observed that HIVþ patients receiving NRTIs had reductions in parietal and frontal gray matter Glu that were predictive of worse cognitive performance. 32 With a larger proportion of HIVþ growing older with the disease, several studies have started to investigate the interaction between HIV and aging using MRS. HIVþ patients have been shown to have significant reductions in Glu to levels Role of Neuroimaging in HIV-Associated Neurocognitive Disorders Masters, Ances 91 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. equivalent to those in HIV-controls a decade older. 32 Another study confirmed these findings by demonstrating that HIVþ patients exhibited age dependent declines in NAA and Gln, such that the metabolic profile of a 30-year-old HIVþ patient was equivalent to a 56-year-old HIV-control. 22 In both instances, though HIV and aging effects were observed, no interaction was present.
Overall, MRS offers a valuable method for monitoring HIVassociated neuropathologic changes. Observed MRS changes may be more sensitive than conventional MRI alone and could augment current neuroimaging protocols. MRS measures may detect subtle early changes associated with HIV infection, and concentrations or ratios of cerebral metabolites measured by MRS could be used as a quantitative indicator of cerebral involvement. In addition, MRS could be used to evaluate the efficacy of therapeutics directed against HIV infection within the CNS during early stages of infection. Some limitations exist in the current MRS HIV research literature, including mostly cross-sectional studies, as well as analyses restricted to specific regions of interest. However, MRS results suggest that contributions of inflammation, aging, and drug toxicity could all contribute to the continued prevalence of HAND. Additional studies that include more HIV-controls are needed. Longitudinal studies, with a focus on repeated imaging of HIVþ patients as they transition through different stages of infection, as well as prior to and after stable cART, are needed. In addition, the impact of comorbidities (e.g., hepatitis, substance abuse, etc.) on MRS measurements should be more fully characterized in HIVþ patients.
Structural Neuroimaging
Volumetrics Analysis of MRI Volumetric MRI examines particular regions of interest and assesses if abnormal structural changes are present in affected individuals compared with healthy controls. 38 This method provides a useful tool to rule out alternate etiologies and can support a diagnosis of HAND. Specific structures or general brain regions (e.g., white and gray matter) are analyzed. 39 A PubMed search using keyword search terms "MRI," "volume," "brain," and "HIV" identifies more than 60 articles. Please see ►Table 2 for a select list of MRI volumetric studies performed in HIVþ patients. Typically, higher field MRI (initially 1.5 T and now 3 T) has been used to acquire high resolution T1-weighted images. In particular, a magnetization prepared rapid acquisition gradient echo (MPRAGE) image provides the greatest contrast for segmenting gray matter, white matter, and CSF. Although not typically acquired with conventional imaging sequences, the MPRAGE sequence can be obtained on most MRI scanners.
Early volumetric work concentrated on measuring ratios of subcortical (e.g., caudate) to intraventricular volumes. This technique could not isolate the location of atrophy and missed brain regions not within the field of view. 40 Semior fully automated methods have been developed for segmenting the brain based on voxel signal intensity properties of tissues. [41] [42] [43] Currently, a variety of preprocessing pro-grams are available, but some experience is needed for analysis.
In the pre-and early antiretroviral era, significant volume loss was observed in the basal ganglia, posterior cortex, and total white matter of HIVþ patients compared with agematched HIV-individuals. [44] [45] [46] Atrophy was greatest in more advanced stages of infection, but changes were seen even in cognitively normal HIVþ individuals. 47 Subsequent studies in the cART era have demonstrated subcortical and cortical atrophy in HIVþ patients 42,48-50 (see ►Fig. 1). HIVþ individuals, especially those with an acquired immunodeficiency syndrome-(AIDS-) defining event, have thinner cortical thickness (primary sensory, and motor), 49 smaller cortical volumes, 28, 42, 49, 51, 52 and larger total ventricular size. 49, 52 Ongoing brain volume loss occurs despite initiation of cART. 28, 50 Changes in brain volume may commence early as cortical atrophy and expansion of the third ventricle are observed in primary HIV infection. 51 Volumetric changes also correlate with NP testing and clinical measures. Several studies have reported structurefunction relations with poorer cognitive or motor performance associated with smaller brain volumes. 30, 49, [53] [54] [55] [56] [57] [58] [59] [60] Both greater viral burden (plasma HIV-1 RNA, CSF HIV-1 RNA, peripheral monocyte DNA) and immune response to the virus (nadir CD4þ T lymphocyte counts) are associated with greater volume loss. 28, 42, 52, 54, 55, [60] [61] [62] Common comorbidities may also contribute to volume abnormalities in HIVþ patients. Hepatitis C coinfection, 42 alcoholism, 55 cigarette smoking, 63 and small-vessel disease 64 may exacerbate brain atrophy in the setting of HIV infection. Furthermore, characteristic volume loss associated with aging may independently affect certain brain structures in older HIVþ individuals. 50, 55, 65, 66 Older HIVþ individuals suffering from multiple comorbidities may experience greater cumulative volume losses, increasing their risk for HIV-induced neurocognitive impairment. 67 Overall, MRI volumetric analysis demonstrates that brain structure abnormalities begin early and progress throughout the course of HIV infection. Brain structural integrity in HIV likely reflects dynamic effects of current immune status and active viral replication, superimposed on possible residual effects associated with severe prior immunosuppression and other comorbidities. Though most MRI volumetric studies have been performed cross sectionally, additional longitudinal studies could assess for risk factors for developing HAND and response to therapy. Future studies should include more HIV-controls for comparison.
Diffusion Tensor Imaging
More recently, diffusion tensor imaging (DTI) has become a popular method for studying white matter structural integrity. 59,68-70 A PubMed search including the keywords "DTI," "brain," and "HIV" identified more than 30 articles. Please see ►Table 3 for a select list of DTI studies performed in HIVþ patients. DTI measures the diffusion of water molecules in white matter. Movement of water can be anisotropic with diffusion greater along the length of the fiber (longitudinal direction) than perpendicular to it (radial or transverse Role of Neuroimaging in HIV-Associated Neurocognitive Disorders Masters, Ances 93 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Role of Neuroimaging in HIV-Associated Neurocognitive Disorders Masters, Ances 95 direction), as myelin may restrict diffusion. 71 For each voxel, a tensor is calculated that describes the three-dimensional shape of diffusion of water. The fiber direction is indicated by the tensor's main eigenvector. Diffusion along the major axis is assumed to reflect diffusivity parallel to the white matter tract. Mean diffusivity (MD) reflects the average diffusion in the major axis and the two minor axes. Fractional anisotropy (FA) is a value between zero and one and provides a measure of the general shape of the ellipsoid. 72 In general, DTI can be performed on conventional MRI scanners, but technical assistance is required. Depending on both the institution and time available for scanning, DTI with either single or multiple diffusion sensitivity parameters ("b values") can be performed. A minimum of six directions is acquired. Conventional preprocessing packages exist, but experience is required for analysis.
Variable results have been observed when DTI has been used to study the effects of HIV on white matter integrity. 60, 66, 68, [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] In general, many studies have shown that HIV leads to an increase in MD and a decrease in FA within white matter tracts (including the corpus callosum [CC] and centrum semiovale [CSO]) (see ►Fig. 2). However, subtle differences exist in the location of these changes depending on the study. [84] [85] [86] [87] For example, Filippi and colleagues showed a decrease in FA and an increase in MD in the genu and splenium of the CC of HIVþ patients. 80 Thurnher and colleagues observed a reduction in FA within the genu of the CC of HIVþ patients. 75 Wu and colleagues reported a reduction in FA within the splenium of the CC in HIVþ individuals. This reduction in FA was associated with worsening motor speed performance. 74 However, Wright and colleagues observed a reduction in MD throughout the CC and CSO of HIVþ patients compared with HIV-controls. 88 Instead of region of interest analyses, a voxelwise analysis can also be performed. Gongvtana and colleagues showed significantly higher MD and lower FA throughout the white matter of HIVþ individuals compared with HIVcontrols. 73 Typically, comparisons have been performed between HIVþ and HIV-controls. HIVþ individuals receiving cART (HIVþ/cARTþ) and those naïve to cART (HIVþ/cART-) have often been merged into a single group. The few studies that have investigated the effects of cART on DTI parameters in HIVþ individuals have shown conflicting results. Pffeferbaum and colleagues demonstrated that HIVþ/cART-individuals had significantly higher MD values in the inferior cingulate bundle, occipital forceps, and superior longitudinal fasciculus compared with HIV-controls or HIVþ/cARTþ. 83 However, Chen and colleagues noted no significant differences in DTI parameters between HIVþ/cART-and HIVþ/cARTþ patients. 89 A decrease in FA was seen in the temporal lobes of HIVþ/cARTþ compared with HIVþ/cART-individuals, 73 suggesting possible neurotoxicity. More recently, Wright and colleagues demonstrated that initiation of cART led to Role of Neuroimaging in HIV-Associated Neurocognitive Disorders Masters, Ances 97 significant increases in MD, but not FA in the CC and CSO of HIVþ patients. 88 In summary, DTI may be a more sensitive method than conventional T2-weighted imaging for detecting subtle changes despite the presence of normal appearing white matter in HIVþ patients. Most DTI studies have been cross sectional, and studied changes in chronic or advanced HIV infection. The effects of early HIV infection or of cART initiation on the white matter have not been systematically assessed by DTI. Furthermore, few DTI studies have included enough HIV-controls. Additional studies comparing DTI parameters to CSF biomarkers and assessing the potential impact of comorbidities need to be performed.
Functional Magnetic Resonance Imaging
A nascent literature has started to develop utilizing blood oxygen-level dependent (BOLD) fMRI to investigate the effects of HIV on brain function. 90 A PubMed search using "fMRI," "BOLD," and "HIV" as keyword search terms yielded nine articles. Although the BOLD sequence can be performed on conventional MRI scanners, additional technical assistance is required for designing functional task paradigms. Preprocessing programs are available, but significant experience is needed.
Fluctuations in the BOLD response within specific brain regions indirectly reveal the coupling between changes in neuronal activity and cerebral blood flow for a particular stimulus. 91 Increases or decreases in brain activation during a task, as compared with rest or a neutral task, are assumed to be related to the cognitive function that is under investigation. 92 HIVþ patients have greater parietal activation for a simple attention task and greater frontal and parietal activation during more complex attention tasks. 93 These BOLD changes in HIVþ patients may reflect increased recruitment of additional areas to meet cognitive demands 32, 33, 56, [93] [94] [95] [96] [97] [98] [99] [100] [101] A recent systematic meta-analysis of BOLD fMRI studies using various functional tasks in HIVþ patients was performed using an activation likelihood estimation (ALE). HIVþ patients had greater functional activation within the left inferior frontal gyrus and caudate nucleus compared with HIV-controls. 102 Dysfunction in this frontostriatal network was qualitatively related to neurocognitive impairment. When assessed at rest, functional connections between brain networks may be compromised in HAND, in ways that are similar to aging. 103 To date, most BOLD fMRI studies have been performed in a limited number of HIVþ patients with most receiving cART. Only a few studies have started to assess the impact of comorbidities such as methamphetamine use. A common task paradigm has not been developed across studies or sites. Additional BOLD fMRI studies are needed to evaluate the efficacy of novel therapies.
The Future of Advanced Neuroimaging
Considerable progress has been made in applying MRI methods to understand neuroHIV. However, most studies have compared HIVþ individuals to HIV-controls with secondary comparisons concentrating on HAND diagnosis or certain laboratory measures or comorbidities. Further studies that investigate the pathophysiology of spread of the disease throughout the brain are needed. These studies could help predict which HIVþ patients are at increased risk for developing HAND. For neuroimaging to take the next step, these techniques need to be included not only within research criteria for HAND, but also in the evaluation of therapeutics. This can be accomplished by using a common protocol at multiple research sites. This protocol should include multiple MRI modalities. A first attempt has been made by the AIDS Clinical Trial Group (ACTG) with multiple sites scanning HIVþ patients using the same imaging paradigm. Results from this pilot study were encouraging and it is hoped that a similar protocol can be rolled out to more sites. Crossmodality comparisons within the same HIVþ individual will provide us a more complete understanding of the HIV pathophysiology. Role of Neuroimaging in HIV-Associated Neurocognitive Disorders Masters, Ances 99 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
